


THE REDOX[®] CIRCULAR

Data current to 31-May-2010

Site #	Institution	May	Cumulative
1	Kingston General		74
2	St. Joseph Healthcare	1	54
3	Ottawa General	6	142
4	Ottawa Civic	1	50
5	Vancouver General	1	20
6	Sacre-Coeur	1	65
7	Maisonneuve-Rosemont	-	15
8	Royal Victoria	-	11
9	Royal Alexandra	2	23
11	Grey Nun's	-	15
13	Victoria General	-	6
14	London HSC	-	15
16	Capital Health, QEII	-	17
19	Montreal General	-	18
20	L'Enfant Jesus	2	26
21	Liege, Belgium	1	8
22	CHUV, Switzerland	-	11
23	Royal Jubilee	-	9
25	Mount Sinai	-	35
26	U of Colorado	1	19


Site #	Institution	May	Cumulative
27	Miami Valley, Ohio	-	8
28	Fletcher Allen, Vermont	1	9
30	U of Louisville	2	15
31	U of Texas	-	6
32	University Hospital	-	7
33	Laval	1	10
34	Emory University	-	-
35	Kiel, Germany	-	3
36	Lubeck, Germany	-	-
37	Greifswald, Germany	2	8
38	Hamburg-Altona, Germany	-	4
39	Jewish Hospital	-	1
40	Atlanticare	1	1
41	Hershey Medical Center	-	-
	Intermountain Healthcare	<i>Starting Q2 2010</i>	
	Mayo Clinic, Arizona	<i>Starting in June</i>	
*number patients from closed sites			18
number patients enrolled in pilot			80
TOTALS		23	803


ENROLMENT COUNTDOWN




Enrollment News

 Congratulations to the team at Atlanticare in Atlantic City, NJ for enrolling their first patient in May!

 The 800th patient was enrolled by the team at Ottawa General, fantastic work!

 We would like to acknowledge the teams at the Royal Alexandra Hospital in Edmonton, l'Hôpital Enfant-Jésus in Quebec City, the University of Louisville in the USA and Greifswald in Germany for each enrolling 2 patients this month.



Our monthly enrollment target is 1pt/site = 38 patients; each month

Attention Pharmacists: Thank you for sending in your local enteral product stock inventory.

Maureen Dansereau, Project Assistant has been collating this information as she prepares to initiate another round of product relabeling. The enteral product relabeling procedures will be similar to what has been done in the past. Stay tuned for more information from Maureen in the coming weeks.

Daily PF Ratio: Please remember that daily PaO₂/FiO₂ (worst) should be collected even if the patient is no longer mechanically ventilated. Refer to Implementation Manual pg. 34 for details.

For patients on an oxygen mask or nasal cannula, we have a study tool available to aid in the conversion of O₂ flow rates into FiO₂. If a patient is on a mask, use what is specified on the venturi mask first. The conversion table can be found at www.criticalcarenutrition.com / REDOX[®] / Resources / Study Procedures

Thank you Pat Thompson at the Royal Alexandra Hospital for this question



Timing for Completion of SF-36 Questionnaires

SF-36 Questionnaires are to be completed at 3 & 6 months following admission to the ICU.

Historically we have allowed for a window of ± 2 weeks for the collection of this data. We have observed that there have been instances when 3 and/or 6 month data has been collected as late as 12 months after ICU admission. Data collected this far outside of the window offers no value for the purposes of the study.

We have examined the time windows for collecting this data and would like to clarify, we will accept follow-up data (i.e. SF-36 questionnaires) within the following time frames:

3-Month: Data collected between 2½ and 4½ months following ICU admission

6-Month: Data collected between 4½ and 7½ months following ICU admission

For any patient where follow-up data was collected outside of the window as specified above, we will not be able to compensate the site for this data as it can not be included in the analysis.

Contact the Project Leader if you have any questions regarding this matter.

FAQ: Are the Selenium (Canadian sites) and Dipeptiven vials latex free?

Regarding the **Selenium vials**, we have received a written statement from the Drug Information and Pharmacovigilance Manager at Sandoz (manufacturer of Selenium) that the stoppers on the vials we supply to the Canadian REDOX[®] sites are made from synthetic polymer-based rubber, the stoppers are 100% synthetic and do NOT contain any natural rubber.

Regarding the **Dipeptiven vials**, we have received a written statement from the Quality Control department at Fresenius-Kabi (manufacturer of Dipeptiven) that the rubber closures do NOT contain natural latex compounds.

Thank you Sherry Weir at the Ottawa Hospital for this question

The Faces of REDOX[®]

**Critical Care Research Group, Royal Alexandra Hospital
Edmonton, Alberta**

Pictured to the right is Dr. Kutsogiannis's team at the Royal Alexandra Hospital. The team at the Royal Alexandra Hospital has been part of the REDOX[®] Study since July 2007.

Great work enrolling 2 REDOX[®] patients in May!

Left to right—Christine Krawchuk, Reagan Bartel, Dr. Kutsogiannis, Pat Thompson, Darlene Jossy and Kirby Scott.



STUDY CHAIR

Daren Heyland
dkh2@queensu.ca

PROJECT LEADERS

Janet Overvelde
overvelj@kgh.kari.net
Rupinder Dhaliwal
dhaliwar@kgh.kari.net

DATA MANAGEMENT

Jennifer Korol
korolj@kgh.kari.net
Shawna Froese
froeses@kgh.kari.net

PROJECT ASSISTANTS

Maureen Dansereau
danserem@kgh.kari.net
Susan Campbell
campbes3@kgh.kari.net